Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.

Authors:
Address: Galveston National Laboratory, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77550-0610, USA. tom.geisbert@utmb.edu
Journal:

Publication:

abstract

The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with a high mortality rate in humans and nonhuman primates. Among the most-promising filovirus vaccines under development is a system based on Recombinant vesicular stomatitis virus (rVSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Importantly, a single injection of blended rVSV-based filovirus vaccines was shown to completely protect nonhuman primates against Marburg virus and 3 different species of Ebola virus. These rVSV-based vaccines have also shown utility when administered as a postexposure treatment against filovirus infections, and a rVSV-based Ebola virus vaccine was recently used to treat a potential laboratory exposure. Here, we review the history of rVSV-based vaccines and pivotal animal studies showing their utility in combating Ebola and Marburg virus infections.

Related Articles
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
J Virol. 2009
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H. J Virol. 2009 Jul; 83(14):7296-304. Epub 2009 Apr 22.
Review Prospects for immunisation against Marburg and Ebola viruses.
Rev Med Virol. 2010
Review Prospects for immunisation against Marburg and Ebola viruses.
Geisbert TW, Bausch DG, Feldmann H. Rev Med Virol. 2010 Nov; 20(6):344-57.
Review Progress in filovirus vaccine development: evaluating the potential for clinical use.
Expert Rev Vaccines. 2011
Review Progress in filovirus vaccine development: evaluating the potential for clinical use.
Falzarano D, Geisbert TW, Feldmann H. Expert Rev Vaccines. 2011 Jan; 10(1):63-77.
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.
Vaccine. 2008
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.
Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, Ströher U, Fritz EA, Hensley LE, Jones SM, et al. Vaccine. 2008 Dec 9; 26(52):6894-900. Epub 2008 Oct 18.
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.
Clin Vaccine Immunol. 2008
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.
Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD. Clin Vaccine Immunol. 2008 Mar; 15(3):460-7. Epub 2008 Jan 23.
Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment.
PLoS One. 2012
Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment.
Talekar A, Pessi A, Glickman F, Sengupta U, Briese T, Whitt MA, Mathieu C, Horvat B, Moscona A, Porotto M. PLoS One. 2012; 7(3):e30538. Epub 2012 Mar 2.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.